Xintela's first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing 3 different dose levels of the stem cell product XSTEM®. All patients at the second dose level have now been dosed. XSTEM, which consists of allogeneic (donated) integrin 101-selected mesenchymal stem cells, is developed and manufactured by Xintela. Patients with moderate knee osteoarthritis (grade II-III) receive an injection of XSTEM into the knee joint. Three different dose levels are being evaluated in up to 54 patients and each patient will be followed for 18 months with efficacy assessments every six months. The primary goal is to show that XSTEM is safe, and also to investigate preliminary efficacy signals, such as reduced breakdown of joint cartilage, regeneration of damaged cartilage, and improved joint function. Safety data and early efficacy results are expected
in 2023.